BA98300A - Pirolidin derivati - Google Patents

Pirolidin derivati

Info

Publication number
BA98300A
BA98300A BA980300A BA980300A BA98300A BA 98300 A BA98300 A BA 98300A BA 980300 A BA980300 A BA 980300A BA 980300 A BA980300 A BA 980300A BA 98300 A BA98300 A BA 98300A
Authority
BA
Bosnia and Herzegovina
Prior art keywords
chem
formula
pyrrolidine derivatives
pyrrolidine
ch2s
Prior art date
Application number
BA980300A
Other languages
Bosnian (bs)
English (en)
Inventor
Alexander Roderick Mackenzie
Peter Edward Cross
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10653525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BA98300(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BA98300A publication Critical patent/BA98300A/bs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
BA980300A 1989-03-17 1998-03-30 Pirolidin derivati BA98300A (bs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898906166A GB8906166D0 (en) 1989-03-17 1989-03-17 Therapeutic agents
YU52790A YU47587B (sh) 1989-03-17 1990-03-16 Pirolidin derivati

Publications (1)

Publication Number Publication Date
BA98300A true BA98300A (bs) 2001-09-14

Family

ID=10653525

Family Applications (1)

Application Number Title Priority Date Filing Date
BA980300A BA98300A (bs) 1989-03-17 1998-03-30 Pirolidin derivati

Country Status (37)

Country Link
US (1) US5096890B1 (fr)
EP (1) EP0388054B1 (fr)
JP (2) JPH0764809B2 (fr)
KR (2) KR920008166B1 (fr)
CN (1) CN1023007C (fr)
AT (1) ATE96783T1 (fr)
AU (1) AU614224B2 (fr)
BA (1) BA98300A (fr)
CA (1) CA2012295C (fr)
CL (1) CL2003002756A1 (fr)
CY (2) CY1812A (fr)
CZ (1) CZ280053B6 (fr)
DD (1) DD292911A5 (fr)
DE (2) DE69004302T2 (fr)
DK (1) DK0388054T3 (fr)
EG (1) EG18951A (fr)
ES (1) ES2060020T3 (fr)
FI (1) FI95573C (fr)
GB (1) GB8906166D0 (fr)
HK (1) HK130294A (fr)
HU (2) HU217433B (fr)
IE (1) IE62515B1 (fr)
IL (1) IL93694A (fr)
LU (1) LU91161I2 (fr)
MX (1) MX9319890A (fr)
MY (1) MY105527A (fr)
NL (1) NL300191I2 (fr)
NO (2) NO176316C (fr)
NZ (1) NZ232958A (fr)
PL (1) PL164136B1 (fr)
PT (1) PT93443B (fr)
RU (2) RU1833374C (fr)
SG (1) SG143394G (fr)
SK (1) SK278434B6 (fr)
UA (1) UA18263A (fr)
YU (1) YU47587B (fr)
ZA (1) ZA901982B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932594A (en) * 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB8928042D0 (en) * 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5486527A (en) * 1990-01-06 1996-01-23 Pfizer Inc. Anticholinergic agents
US5607950A (en) * 1990-01-06 1997-03-04 Pfizer Inc. Muscarinic receptor antagonists
NZ251610A (en) * 1992-04-23 1996-02-27 Merrell Dow Pharma 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
US6017931A (en) * 1994-03-01 2000-01-25 Fmc Corporation Insecticidal compositions containing n-(substituted phenylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
US5639763A (en) * 1994-03-01 1997-06-17 Fmc Corporation Insecticidal N-(substituted arylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
WO1996003396A1 (fr) * 1994-07-27 1996-02-08 The Procter & Gamble Company Dihydrobenzofurane et composes apparentes utiles comme agents anti-inflammatoires
US5656661A (en) * 1994-07-27 1997-08-12 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5672620A (en) * 1996-02-01 1997-09-30 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US5684031A (en) * 1996-02-01 1997-11-04 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
ATE235903T1 (de) * 1996-12-02 2003-04-15 Kyorin Seiyaku Kk Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
US6131129A (en) * 1997-07-30 2000-10-10 Sony Corporation Of Japan Computer system within an AV/C based media changer subunit providing a standarized command set
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
US6890920B2 (en) * 2001-10-26 2005-05-10 Pharmacia & Upjohn Company Quaternary ammonium compounds
SE0103668D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive blader
EP1441706A2 (fr) * 2001-11-05 2004-08-04 Pharmacia & Upjohn Company Aerosol antimuscarinique
GB0129962D0 (en) * 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
CA2492121A1 (fr) 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited Derives d'azabicyclo[3.1.0]hexanes 3,6-disubstitues utiles comme antagonistes des recepteurs muscariniques
AU2002368152A1 (en) 2002-07-31 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0)hexane derivatives useful as muscarinic receptor antagonists
EP1545508A4 (fr) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd Derives d'azabicyclo ¬3.1.0 hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
ATE423769T1 (de) 2002-08-23 2009-03-15 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP2177511A2 (fr) 2002-12-10 2010-04-21 Ranbaxy Laboratories Limited Procédé de préparation de dérivés 3,6-disubstitués d'azabicyclo
EP1581522B1 (fr) 2002-12-23 2008-02-20 Ranbaxy Laboratories Limited Derives de flavaxate comme antagonistes de recepteurs muscariniques
US7465751B2 (en) 2002-12-23 2008-12-16 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615881A2 (fr) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyle et composes apparentes ayant les activites agoniste du recepteur beta2 adrenergique et antagoniste de recepteur de muscarinic
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003214535B2 (en) 2003-04-10 2009-09-03 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP2006522787A (ja) 2003-04-11 2006-10-05 ランバクシー ラボラトリーズ リミテッド ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体
WO2004091597A2 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Procede pour traiter le syndrome du colon irritable
US20040242569A1 (en) * 2003-04-15 2004-12-02 Pfizer Inc. Quatemary ammonium compounds
CA2522666A1 (fr) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Polytherapies
TW200510298A (en) 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
US7368463B2 (en) 2003-07-11 2008-05-06 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
WO2005087722A1 (fr) * 2004-03-11 2005-09-22 Theravance, Inc. Composes biphenyle convenant en tant qu'antagonistes du recepteur muscarinique
EP1723142A1 (fr) * 2004-03-11 2006-11-22 Theravance, Inc. Composes de diphenylmethyle, antagonistes du recepteur muscarinique
EP1746998A1 (fr) * 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Therapie combinee destinee a reduire les symptomes des voies urinaires
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
US20070197630A1 (en) * 2005-12-27 2007-08-23 Valeriano Merli Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
AR062676A1 (es) 2006-09-07 2008-11-26 Medichem Sa Procedimiento mejorado para preparar compuestos de pirrolidina 1,3-disustituidas
EP2114972A2 (fr) * 2006-12-13 2009-11-11 Gilead Sciences, Inc. Monophosphates utilisés comme promédicaments mutuels d'antagonistes des récepteurs muscariniques et de beta-agonistes dans le traitement de la b.p.c.o. et de la bronchite chronique
EP2109601A2 (fr) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Préparation de darifénacine et ses sels
BRPI0807615A8 (pt) * 2007-02-23 2017-12-05 Theravance Inc Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico
WO2008126106A2 (fr) * 2007-04-16 2008-10-23 Manne Satyanarayana Reddy Procédés nouveaux et perfectionnés pour la préparation d'intermédiaires de darifénacine, de la darifénacine et de ses sels pharmaceutiquement acceptables
US20100204296A1 (en) * 2007-06-08 2010-08-12 Actavis Group Ptc Ehf Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
EP2160372A1 (fr) * 2007-06-15 2010-03-10 Medichem, S.A. Procédé de détermination de la pureté énantiomérique de la darifénacine et de ses intermédiaires
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125430A2 (fr) * 2008-03-17 2009-10-15 Matrix Laboratoires Limited Procédé perfectionné pour la fabrication de darifénacine
WO2009122997A1 (fr) * 2008-04-02 2009-10-08 株式会社カネカ Procédé de fabrication de (s)-3-(1-cyano-1,1-diphénylméthyl)-pyrrolidine
US20110144354A1 (en) * 2008-09-22 2011-06-16 Watson Pharma Private Limited Process for Preparation of Darifenacin and Intermediates Used in the Process
EP2236509A1 (fr) 2009-04-01 2010-10-06 Ragactives, S.L. Méthode de préparation de dérivés de la pyrrolidine 1,3 substituée
AU2010247141A1 (en) 2009-05-15 2011-12-15 Redx Pharma Plc Redox drug derivatives
WO2011070419A1 (fr) 2009-12-10 2011-06-16 Aurobindo Pharma Limited Procédé perfectionné pour la préparation de bromhydrate de darifénacine
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
CN101857581A (zh) * 2010-06-22 2010-10-13 浙江美诺华药物化学有限公司 一种制备达非那新中间体5-(2-溴乙基)-2,3-二氢-1-苯并呋喃的方法
WO2011161504A1 (fr) 2010-06-23 2011-12-29 Micro Labs Limited Formulations à libération prolongée contenant de la darifénacine ou des sels pharmaceutiquement acceptables de celle-ci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1057145A (en) * 1963-08-16 1967-02-01 Bellon Labor Sa Roger Phenylcyclohexylacetonitrile derivatives
US4002766A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
US4594343A (en) * 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
IL76583A (en) * 1984-10-19 1988-08-31 Robins Co Inc A H 1-(aminoalkyl)-alpha'alpha-diaryl pyrrolidinyl,piperidino and homopiperidino acetamides and acetonitriles and pharmaceutical compositions containing them
EP0235463A3 (fr) * 1985-12-20 1990-01-17 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Arylalkyl et arylalkylène piperidines substitués sur l'azote utilisés comme agents antihistaminiques cardiovasculaires et antisécrétion
IL78939A (en) * 1986-01-17 1990-04-29 Robins Co Inc A H Pharmaceutical compositions containing n-substituted arylalkyl-and arylalkylene-piperidines and tetrahydropyridines and certain such novel compounds

Also Published As

Publication number Publication date
CY2005005I1 (el) 2010-07-28
HU901580D0 (en) 1990-06-28
CY2005005I2 (el) 2010-07-28
US5096890B1 (en) 1995-03-28
FI901333A0 (fi) 1990-03-16
FI95573B (fi) 1995-11-15
EP0388054A1 (fr) 1990-09-19
ES2060020T3 (es) 1994-11-16
IE62515B1 (en) 1995-02-08
CA2012295C (fr) 1996-11-12
HK130294A (en) 1994-12-02
JPH02282360A (ja) 1990-11-19
ATE96783T1 (de) 1993-11-15
FI95573C (fi) 1996-02-26
IL93694A0 (en) 1990-12-23
ZA901982B (en) 1991-10-30
JPH07149640A (ja) 1995-06-13
YU47587B (sh) 1995-10-24
CN1045580A (zh) 1990-09-26
KR960015142B1 (ko) 1996-11-01
PT93443A (pt) 1990-11-07
DD292911A5 (de) 1991-08-14
NO2005008I2 (no) 2006-11-27
NO176316B (no) 1994-12-05
PL164136B1 (pl) 1994-06-30
IL93694A (en) 1994-08-26
CZ280053B6 (cs) 1995-10-18
SK129590A3 (en) 1997-05-07
RU2015965C1 (ru) 1994-07-15
NO901241L (no) 1990-09-18
CA2012295A1 (fr) 1990-09-17
NL300191I2 (nl) 2005-08-01
AU614224B2 (en) 1991-08-22
LU91161I2 (fr) 2005-06-13
IE900955L (en) 1990-09-17
CL2003002756A1 (es) 2005-02-11
DE69004302T2 (de) 1994-02-24
CY1812A (en) 1995-10-20
KR920008166B1 (ko) 1992-09-24
EG18951A (en) 1994-03-30
AU5140290A (en) 1990-09-20
EP0388054B1 (fr) 1993-11-03
DE122005000022I1 (de) 2005-08-04
JPH0764809B2 (ja) 1995-07-12
RU1833374C (ru) 1993-08-07
KR900014367A (ko) 1990-10-23
CZ129590A3 (en) 1995-05-17
UA18263A (uk) 1997-12-25
YU52790A (sh) 1992-07-20
NO176316C (no) 1995-03-15
DK0388054T3 (da) 1993-12-06
DE69004302D1 (de) 1993-12-09
GB8906166D0 (en) 1989-05-04
SK278434B6 (en) 1997-05-07
HUT58313A (en) 1992-02-28
MY105527A (en) 1994-10-31
US5096890A (en) 1992-03-17
NZ232958A (en) 1992-05-26
NO901241D0 (no) 1990-03-16
SG143394G (en) 1995-01-13
HU211640A9 (en) 1995-12-28
HU217433B (hu) 2000-01-28
NL300191I1 (nl) 2005-07-01
PT93443B (pt) 1996-02-29
CN1023007C (zh) 1993-12-08
MX9319890A (es) 1993-08-01
DE122005000022I2 (de) 2006-02-02
NO2005008I1 (en) 2005-04-11

Similar Documents

Publication Publication Date Title
US5096890B1 (en) Pyrrolidine derivatives
DE69007126D1 (de) Muscarin-rezeptor-antagonisten.
FI922835A0 (fi) Menetelmä terapeuttisesti aktiivisten piperidiinijohdannaisten valmistamiseksi
DE69006745T2 (de) Muscarin-rezeptor-antagonisten.